Golimumab Simponi®
Golimumab is a fully human monoclonal antibody directed against tumour necrosis factor alpha. The SHIKARI® Golimumab portfolio separates quantitative drug-concentration measurement from quantitative and qualitative anti-drug antibody analysis, allowing researchers to select the analyte and measurement mode required by their study design.
Why Golimumab is relevant to biological-drug monitoring research
Golimumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Golimumab is a fully human IgG1κ monoclonal antibody directed against TNF-α, binding soluble and transmembrane forms of the cytokine. Source ↗
Approved Indications
EMA-authorised uses include rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis and polyarticular juvenile idiopathic arthritis in defined age and treatment settings. EMA source ↗
Indication-Specific Trough Exposure
FDA pharmacokinetic data show different steady-state trough concentrations by indication and regimen:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Three complementary research assays
Enzyme immunoassay for the quantitative determination of golimumab in human serum and plasma. Developed for concentration measurement across the Cmin–Cmax range in trough-level, pharmacokinetic and biosimilar research.
Enzyme immunoassay for the quantitative determination of specific antibodies to golimumab in human serum and plasma, with confirmation. Designed for anti-drug antibody quantification and longitudinal immunogenicity research.
Enzyme immunoassay for the qualitative determination of specific antibodies to golimumab in human serum and plasma. Designed for positive/negative anti-drug antibody screening. No standard curve is shown because this is a qualitative assay.
Kit Specifications at a Glance
| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-GOL | GOL-FD-SIM | Drug Levels | Golimumab | Quantitative ELISA | 96 | 2–8°C |
| SHIKARI® S-ATG with confirmation | GOL-QNS-SIM | Quantitative ADA | Anti-golimumab antibodies | Quantitative ADA ELISA with confirmation | 96 | 2–8°C |
| SHIKARI® S-ATG qualitative | GOL-QLS-SIM | Qualitative ADA | Anti-golimumab antibodies | Qualitative ADA ELISA | 96 | 2–8°C |
* Store at +4°C and refer to the current protocol supplied with the kit. Shipping: room temperature.
Which kit fits your research question?
Choose the assay by analyte and measurement mode rather than treating drug-concentration and anti-drug antibody results as equivalent.
Publications Using SHIKARI® Golimumab Kits 2
All journal publications below are drawn from the Matrix Biotek Publications library and are shown newest first. Records are included when the publication database identifies the biological drug and SHIKARI® product use.
Ready to order, or need technical guidance?
Matrix Biotek can help identify the appropriate Golimumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.